The liquid biopsy market was valued at USD 2.6 billion in 2021, and it is anticipated to grow further till USD 13.4 billion by 2031, at a CAGR of 17.8% during the forecast period.
Liquid biopsy is an easy, quick, non-invasive, and repeatable sampling technique that can reflect changes in tumor gene expression profiles and offer a solid foundation for a customized treatment and cancer early detection. The focus in recent years has also been on early cancer detection, tracking the development of tumors, evaluating therapy response and clinical prognosis, and identifying recurrent and refractory cancers. Furthermore, due to technological advancements in both practicality and turnaround time, liquid biopsy has recently attracted a lot of attention as a non-invasive substitute procedure for tissue biopsy in patients with cancer.
View The Full Report Here –https://www.globalinsightservices.com/reports/liquid-biopsy-market/?utm_id=Pranalip
Market Trends and Drivers
The number of persons who have cancer has significantly increased on a global scale. Environmental factors, cigarette use, infectious diseases like Hepatitis B and C, as well as lifestyle changes, are some of the causes of the increased incidence of cancer. Cancer is the second-leading cause of mortality worldwide, according to the WHO. According to estimates from the International Agency for Research on Cancer (IARC), there would be 19.3 million new cases of cancer and 9.96 million cancer-related deaths worldwide in 2020. Compared to conventional cancer diagnostic methods, liquid biopsy has various advantages, including lower cost, early prognosis, therapy monitoring, tumour heterogeneity identification, acquired drug resistance, and patient comfort (by eliminating the need for surgery).
Market Restraints and Challenges
The quantities of ctDNA of any particular cancer mutation may be very low in the plasma of a cancer patient, especially after treatment or surgery, making the detection of ctDNA in liquid biopsies technically difficult. According to sampling statistics, there may be fewer than one detectable copy of the cancer mutation-containing ctDNA in any one patient’s plasma sample. As a result, even though ctDNA is present in the plasma but at a low level, it might not be picked up in the patient sample. This affects the informative value of the liquid biopsy tests for cancer by producing false-negative results where ctDNA is present but not identified.
Request A Sample Of This Report –https://www.globalinsightservices.com/request-sample/GIS10319/?utm_id=Pranalip
Market Segments
BIOMARKER TYPE – ctDNA, CTCs, Exosomes, Others, APPLICATION – Oncology, NIPT, Transplant Diagnostics, Others, TECHNOLOGY – Next-Generation Sequencing, Polymerase Chain Reaction, Droplet Digital PCR, Circulating Tumor Cells, Others, SAMPLE TYPE – Blood, Urine, Saliva, Others, CANCER TYPE – Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Other Cancers, END USER – Hospitals, Research Institutes, Others, CLINICAL APPLICATION – Early Cancer Detection, Treatment Monitoring, Recurrence Monitoring, Therapy Selection
Major Players in the Global Liquid Biopsy Market
The key players studied in the report are F. Hoffmann-La Roche Ltd. (Switzerland), Myriad Genetics, Inc. (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific, Inc. (US), Guardant Health, Inc. (US), MDxHealth SA (Belgium), Exact Sciences Corporation (US), Illumina Inc. (US), Sysmex Inostics (US), Bio-Rad Laboratories, Inc. (US), Biocept, Inc. (US), NeoGenomics, Inc. (US), ANGLE plc (UK), Menarini-Silicon Biosystems (Italy), and Vortex Biosciences, Inc. (US) among others.
Customise This Report As Per Your Requirements –https://www.globalinsightservices.com/request-customization/GIS10319/?utm_id=Pranalip
COVID-19 Impact
Although COVID-19’s far-reaching consequences have been unprecedented, cancer sufferers have been among the most severely impacted groups. The number of patients getting cancer screening, diagnosis, and treatment has been significantly impacted by COVID-19. Oncology clinics were re-profiled for treating patients with the COVID-19 as a result of the increasing demand brought on by the rising rate of COVID-19 patients being hospitalized. As a result, a study found that numerous diagnostic and therapeutic operations, including up to 2.3 million cancer surgeries, have been shelved or delayed globally.
However, as nations gradually loosen their travel restrictions, testing numbers are expected to increase again. Responding to rising cancer incidence has become a critical medical concern on a global scale since the COVID-19 pandemic. Cancer has been recognized as a risk factor for COVID-19 due to the fact that several COVID-19 patients had malignancies. It is predicted that additional research in this area would advance cancer research by helping to better understand the dynamics of infection. It is also anticipated that this will increase demand for liquid biopsy products.
Buy Now-https://www.globalinsightservices.com/checkout/single_user/GIS10319/?utm_id=Pranalip
Research Scope
- Scope – Highlights, Trends, Insights. Attractiveness, Forecast
- Market Sizing – Product Type, End User, Offering Type, Technology, Region, Country, Others
- Market Dynamics – Market Segmentation, Demand and Supply, Bargaining Power of Buyers and Sellers, Drivers, Restraints, Opportunities, Threat Analysis, Impact Analysis, Porters 5 Forces, Ansoff Analysis, Supply Chain
- Business Framework – Case Studies, Regulatory Landscape, Pricing, Policies and Regulations, New Product Launches. M&As, Recent Developments
- Competitive Landscape – Market Share Analysis, Market Leaders, Emerging Players, Vendor Benchmarking, Developmental Strategy Benchmarking, PESTLE Analysis, Value Chain Analysis
- Company Profiles – Overview, Business Segments, Business Performance, Product Offering, Key Developmental Strategies, SWOT Analysis.
With Global Insight Services, you receive:
10-year forecast to help you make strategic decisions
- In-depth segmentation which can be customized as per your requirements
- Free consultation with lead analyst of the report
- Infographic excel data pack, easy to analyze big data
- Robust and transparent research methodology
- Unmatched data quality and after sales service
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.